Intensive multi-disciplinary care for patients with brain metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This health services intervention focuses on comparing the effects of intensive multi-disciplinary care (IMDC) against standard care for patients with newly diagnosed brain metastases. The study involves a cohort of patients who will receive either standard of care or IMDC, which includes input from various specialists such as medical oncology, neurosurgery, and palliative care. The aim is to assess the impact of this systematic approach on patient-reported symptoms and prognostic awareness. By ensuring consistent access to multi-disciplinary discussions, the study seeks to improve the overall management of brain metastases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients of all genders must be at least 18 years of age.
* Patients must have histologically confirmed, newly diagnosed brain metastases from known or suspected solid tumor primary neoplasms.
* Patients must be able to accurately provide self-report data (e.g. per clinical judgment, cognitive function is intact).
* Patients must be able to complete questionnaires in English.
* Patients must have the ability to provide informed consent.

Exclusion Criteria:

* Patients who are \< 18 years of age are not eligible.
* Patients who are Pregnant are not eligible.

Where it's running

• University of Vermont Medical Center
  Burlington, Vermont, United States Recruiting

Study contacts

• Study coordinator: Alissa A Thomas, MD
• Email: athoma21@med.uvm.edu
• Phone: 802-847-8400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tarlatamab for Small Cell Lung Cancer with Brain Metastases

  This phase II study tests whether tarlatamab can help adults with small cell lung cancer that has spread to the brain, by treating both systemic disease and brain tumors.

  Recruiting at 3 sites Phase 2 Maastricht University Medical Center · Amsterdam and 3 other locations · NCT07402343

• AI-assisted diagnosis for malignant brain tumors

  This project will test an AI system that uses routine preoperative MRI scans to automatically segment and classify malignant brain tumors in adults to help guide diagnosis and care.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang and 1 other locations · NCT07198256

• Same-day stereotactic radiation with reduced planning margins for growing or changing brain metastases

  This trial will try to see if doing MRI planning and stereotactic radiation on the same day, with either a 0 mm or 1 mm treatment margin, helps adults with growing or unstable brain metastases stay on target and reduce side effects.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT07132190

• Preventing first seizures with levetiracetam in patients with motor cortex brain metastases

  This test will try giving levetiracetam to adults with motor cortex brain metastases who have never had a seizure to see if it prevents a first seizure compared with not giving the drug.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT07130786

• Avoiding brain radiation when systemic therapy already targets brain metastases

  This pilot trial tests whether patients with brain metastases who respond to systemic therapy can skip brain radiation.

  Recruiting Phase 2 University of Vermont Medical Center · Burlington, Vermont · NCT06974370

• Using ex vivo pharmacoscopy to guide treatment for brain metastases

  This project will test whether pharmacoscopy, a lab test that screens a patient's tumor cells against many drugs, can help pick effective treatments for adults having surgery for brain metastases.

  Recruiting at 2 sites Phase 2 University of Zurich · Basel and 2 other locations · NCT06620380

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.